|

pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine Clinical Trials

1 actively recruiting trial across 1 location

Also known as: IGFBP-2 plasmid-based DNA vaccine, IGFBP-2 vaccine

Pipeline

Phase 2: 1

Top Sponsors

  • University of Washington1

Indications

  • Primary Peritoneal Carcinoma1
  • Fallopian Tube Carcinoma1
  • Ovarian Carcinoma1
  • Cancer1

Seattle, Washington1 trial

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.